• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2021 Financial and Operating Results and Provides Business Update

    10/18/21 4:30:00 PM ET
    $RFL
    Real Estate
    Finance
    Get the next $RFL alert in real time by email

    We expect Rafael Pharmaceuticals to report top line data from its AVENGER 500 Phase 3 registrational clinical trial in metastatic pancreatic cancer this calendar year

    We expect to submit our previously announced merger with Rafael Pharmaceuticals to our stockholders for a vote this calendar year

    The second and final interim futility analysis of Rafael Pharmaceuticals' Phase 3 clinical trial in AML is planned for this calendar year

    On August 24, 2021, we closed a private investment in public equity (PIPE) financing and received net proceeds of approximately $97.8 million

    NEWARK, N.J., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE:RFL), is focused on developing novel cancer metabolism therapeutics through its Barer Institute, investment in Rafael Pharmaceuticals, Inc. ("Rafael Pharmaceuticals"), a privately held, late-stage clinical oncology company focused on cancer metabolism-based therapeutics, and other early-stage companies, today reported its financial results for the three and twelve months ended July 31, 2021, and provided a business update.

    "We are pleased to have attracted a team of high caliber experienced senior pharmaceutical executives to lead the critical operational functions as we prepare for the top line data readout of Rafael Pharmaceuticals' Phase 3 registrational clinical trial for its lead investigational agent, CPI-613® (devimistat), for the treatment of metastatic pancreatic cancer, and if results warrant, prepare for an NDA submission," said Ameet Mallik, Chief Executive Officer of Rafael Holdings, Inc. "We are pleased with the progress across the pipeline, including the ongoing and planned Rafael Pharmaceuticals' clinical trial programs across multiple indications as well as our early-stage pipeline at the Barer Institute.

    Rafael Holdings, Inc. (the "Company") Updates

    • Recent Experienced Executive Leadership Appointments:



      • On October 6, 2021, we announced the appointment of Mary Margaret (Mimi) Huizinga, MD, MPH, as Chief Development and Medical Officer, effective October 18, 2021. Dr. Huizinga recently served as the Head of US Oncology Medical for Novartis.
      • On September 24, 2021, we announced the appointment of Ashok Marin, Chief Legal Officer. Previously Ashok served as Vice President, Deputy General Counsel, Chief Compliance Officer & Chief Privacy Officer, at Immunomedics, Inc.
      • On September 14, 2021, we announced the appointment of Patrick Fabbio as Chief Financial Officer. Previously, Pat was Chief Financial Officer of WindMIL Therapeutics Inc.
      • On August 17, 2021, we announced the appointment of Melissa Lozner as Chief Compliance & Ethics Officer. Previously, Melissa was Vice President, Head of Ethics, Risk & Compliance at Novartis.
      • On August 17, 2021, we also announced the appointment of Brandi Robinson as Chief Corporate Affairs Officer. Previously, Brandi was SVP & Chief Communications Officer at Mallinckrodt.



    • Effective September 24, 2021, the Company entered into and subsequently funded a $25.0 million Line of Credit Loan Agreement with Rafael Pharmaceuticals. On August 24, 2021, we announced the closing of a private investment in public equity ("PIPE") financing. The Company received net proceeds of approximately $97.8 million, after deducting placement agent fees and other offering expenses.  The PIPE financing was supported by a consortium of new and existing institutional investors with expertise in health care. Institutional and other accredited investors purchased an aggregate of 2,833,425 shares of the Company's Class B common stock at a price of $35.00 per share, and an accredited investor affiliated with Howard Jonas has purchased 112,561 shares at a price of $44.42 per share, which was the closing price of a share of the Company's Class B common stock reported on the New York Stock Exchange on August 19, 2021.



    • On June 21, 2021, we announced that we entered into a merger agreement to acquire full ownership of Rafael Pharmaceuticals to form a focused late-stage clinical oncology company. The Boards of Directors of the two companies, as well as a special independent committee of the Company's Board of Directors, have unanimously approved the merger agreement that provides for the combination of the two companies. We expect to submit our previously announced merger with Rafael Pharmaceuticals to our stockholders for a vote this calendar year

    Rafael Pharmaceuticals, Inc. Updates

    • On September 27, 2021, Rafael Pharmaceuticals announced that the Phase 1 clinical trial of CPI-613® (devimistat) in combination with hydroxychloroquine in patients with relapsed clear cell sarcoma was open for enrollment. The clinical trial will begin enrolling patients at City of Hope in Duarte, California, with other sites across the country to quickly follow.



    • On August 25, 2021, Rafael Pharmaceuticals announced the successful completion of a Phase 1b clinical trial of CPI-613® (devimistat) in combination with gemcitabine and cisplatin in patients with biliary tract cancer. In collaboration with Michigan Medicine, the Phase 1b study consisted of a multicenter trial of gemcitabine and cisplatin with devimistat as first-line therapy for patients with locally advanced unresectable or metastatic biliary tract cancer who have had no prior treatment. The Phase 1b part of the trial has successfully identified the recommended Phase 2 dose of CPI-613 when given in combination with gemcitabine and cisplatin in this patient population. The 2:1 randomized Phase 2 part of the trial has already started enrolling patients and will now determine the efficacy of devimistat at this maximum tolerated dose in combination with gemcitabine and cisplatin as compared with the combination chemotherapy alone.



    • On July 1, 2021, Rafael Pharmaceuticals announced the positive outcome from its preplanned interim futility analysis of its pivotal Phase 3 trial (ARMADA 2000) of CPI-613® (devimistat) for relapsed or refractory acute myeloid leukemia (AML) as determined by an independent Data Monitoring Committee (IDMC). The IDMC recommended to continue the trial as is.



    • On June 29, 2021, Rafael Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for CPI-613® (devimistat) for the treatment of biliary cancer.

    Rafael Holdings, Inc. Fourth Quarter 2021 Financial Results

    As of July 31, 2021, we had cash, and cash equivalents of approximately $7.9 million and a balance in Investments – Hedge Funds valued at $5.3 million.

    For the three months ended July 31, 2021, we incurred a net loss of approximately $12.5 million, a loss of $0.75 per share, which includes approximately $5.6 million in non-cash stock-based compensation. For the same period in the prior year, we incurred a net loss of approximately $5.5 million, or $0.34 per share, which includes approximately $0.1 million in non-cash stock-based compensation.

    Our revenues for the fourth quarter of fiscal 2021 amounted to approximately $1 million, compared to revenues of approximately $1.2 million in the fourth quarter of fiscal 2020.

    Research and development expenses were approximately $1.6 million for the three months ended July 31, 2021. For the same period in the prior year, R&D expenses were approximately $1.1 million.

    Our selling, general and administrative expenses were approximately $12.1 million for the three months ended July 31, 2021, which includes $5.6 million in non-cash stock-based compensation expense. For the same period in the prior year, SG&A expenses were approximately $2.8 million. The increase was primarily driven by an increase in non-cash stock-based compensation expense, increased payroll expense as we started to build our management team, as well as an increase in legal and professional fees.

    Rafael Holdings, Inc. Full Year Fiscal 2021 Financial Results

    For the twelve months ended July 31, 2021, we incurred a net loss of $24.8 million, a loss of $1.49 per share, which includes approximately $6.6 million in non-cash stock-based compensation. For the same period in the prior year, we incurred a net loss of $10.8 million, or $0.66 per share, which includes approximately $0.7 million in non-cash stock-based compensation.

    Our research and development expenses were approximately $4.9 million for the twelve months ended July 31, 2021. For the same period in the prior year, R&D expenses were approximately $2.4 million. The year over year increase in R&D expenses of approximately $2.5 million was driven primarily by increased activity at the Barer Institute.

    Our selling, general and administrative expenses were approximately $20.4 million for the twelve months ended July 31, 2021. For the same period in the prior year, SG&A expenses were approximately $9.1 million. The year over year increase of approximately $11.3 million was primarily driven by an increase in non-cash stock-based compensation expense of $5.9 million, increased payroll expense as we started to build our management team, as well as an increase in legal and professional fees.

    About Rafael Holdings, Inc.

    Rafael Holdings is focused on the development of novel cancer therapies. The company owns the Barer Institute and is a significant investor in two clinical stage oncology companies, Rafael Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd. Through its wholly owned Barer Institute subsidiary, the company is developing a pipeline of compounds focused on the regulation of cancer metabolism. On June 21, 2021, we announced that it has entered into a merger agreement to acquire full ownership of Rafael Pharmaceuticals, Inc. For more information, visit www.rafaelholdings.com.

    About Rafael Pharmaceuticals, Inc.

    Rafael Pharmaceuticals is a clinical-stage oncology company focused on selectively targeting cancer metabolic pathways while simultaneously harnessing the immune system to attack hard-to-treat cancers. The Company's lead drug, CPI-613® (devimistat), is being evaluated in multiple clinical studies including two Phase 3 registrational clinical trials for metastatic pancreatic cancer and r/r acute myeloid leukemia. Multiple Phase 1/2 clinical trials are ongoing or planned in Biliary, r/r Burkitt, r/r Clear Cell Sarcoma, r/r T-cell lymphoma, r/r MDS, and Colorectal cancer. The Company's investors include Rafael Holdings, Inc. (NYSE:RFL). For more information, please visit www.rafaelpharma.com.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; plans and timing for the release of additional clinical data; and the potential of our pipeline, including our internal cancer metabolism research programs. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of public health threats, including COVID-19, on our business and operations; we depend heavily on the success of Rafael Pharmaceuticals and the future success of its lead product candidate devimistat (CPI-613® (devimistat)), and clinical trials of the product candidate may not be successful; our pharmaceutical companies may not be able to develop any medicines of commercial value; our pharmaceutical companies may not be successful in their efforts to identify or discover potential product candidates; the manufacturing and manufacturing development of our products and product candidates present technological, logistical and regulatory risks, each of which may adversely affect our potential revenue; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process; interim, topline and preliminary data may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data; our product candidates may cause serious adverse side effects; ongoing regulatory obligations; effects of significant competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; failure to attract, retain and motivate qualified personnel; the possibility of system failures or security breaches; risks relating to intellectual property and significant costs as a result of operating as a public company. These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended July 31, 2021, and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

    Contact:

    Barbara Ryan

    [email protected]

    (203) 274-2825







    RAFAEL HOLDINGS, INC.
      
    CONSOLIDATED BALANCE SHEETS  
     (audited, in thousands, except share and per share data)  
            
      July 31, July 31,
       2021

       2020

     
    ASSETS    
    CURRENT ASSETS    
    Cash and cash equivalents $7,854  $6,206 
    Restricted cash  5,000   - 
    Trade accounts receivable, net of allowance for doubtful accounts of

    $193 and $218 at July 31, 2021 and 2020, respectively
      235   267 
    Due from Rafael Pharmaceuticals  600   118 
    Prepaid expenses and other current assets  1,075   273 
    Assets held for sale  0   2,968 
    Total current assets  14,764   9,832 
         
    Property and equipment, net  43,238   44,433 
    Equity investment – RP Finance  575   192 
    Due from RP Finance LLC  7,500   - 
    Investments – Rafael Pharmaceuticals  79,141   70,018 
    Investments – Other Pharmaceuticals  477   1,201 
    Investments – Hedge Funds  5,268   7,510 
    Deferred income tax assets, net  0   6 
    In-process research and development and patents  1,575   1,575 
    Other assets  1,517   1,580 
    TOTAL ASSETS $154,055  $136,347 
         
    LIABILITIES AND EQUITY    
    CURRENT LIABILITIES    
    Trade accounts payable $1,160  $921 
    Accrued expenses  1,227   1,191 
    Amount due for purchase of membership interest  -   3,500 
    Due to related parties  136   - 
    Notes payable, net of debt issuance costs  14,528   - 
    Other current liabilities  252   115 
         Total current liabilities  17,303   5,727 
         
    Other liabilities  48   92 
    TOTAL LIABILITIES  17,351   5,819 
         
    COMMITMENTS AND CONTINGENCIES    
    EQUITY    
        Class A common stock, $0.01 par value; 35,000,000 shares authorized, 787,163 shares issued and

        outstanding as of July 31, 2021 and July 31, 2020, respectively
      8   8 
        Class B common stock, $0.01 par value; 200,000,000 shares authorized, 16,947,066 issued and   

        16,936,864 outstanding as of July 31, 2021, and 15,034,598 issued and 15,028,536 outstanding as of

        July 31, 2020
      169   149 
        Additional paid-in capital  159,136   129,136 
        Accumulated deficit  (40,799)  (16,255)
        Accumulated other comprehensive income related to foreign currency translation adjustment  3,772   3,762 
             Total equity attributable to Rafael Holdings, Inc.  122,286   116,800 
        Noncontrolling interests  14,418   13,728 
    TOTAL EQUITY      136,704  130,528 
          
    TOTAL LIABILITIES AND EQUITY $154,055 $136,347 







    RAFAEL HOLDINGS, INC.
    CONSOLIDATED STATEMENTS OF OPERATIONS
     (in thousands, except share and per share data)



     (unaudited)

    For the three months ended
     (audited)

    For the twelve months ended
     7/31/2021 7/31/2020 7/31/2021 7/31/2020
    Revenues$969  $1,240  $3,971  $4,910 
    SG&A Expenses 12,051   2,775             20,416   9,118 
    R&D Expenses               1,562   1,064             4,907   2,391 
    Depreciation and amortization 381   453   1,460   1,866 
    Impairment - Altira      -   -   7,000      - 
    Operating Loss (13,025)  (3,052)         (29,812)  (8,465)
    Unrealized gain on investments 587   1,893   4,758   2,385 
    Other, net 100   505   77   836 
    Loss before Incomes Taxes (12,538)  (1,664)  (25,131)  (6,916)
    Taxes (5)  (5)  (18)  (29)
    Impairment of equity method in Altira      -   (4,000)  -   (4,000)
    Equity in Earnings of RP Finance 95   139   383   192 
    Net loss (12,448)  (5,530)  (24,766)  (10,753)
    Net loss attributable to noncontrolling interests (68)  (125)  (222)  (338)
    Net loss attributable to Rafael Holdings, Inc.$(12,380) $(5,405) $(24,544) $       (10,415)
    Loss Per Share$(0.75) $(0.34) $(1.49) $            (0.66)
            
    Weighted average shares in calculation 16,522,686   15,764,829   16,522,686   15,764,829 

     



    Primary Logo

    Get the next $RFL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RFL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $RFL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

      NEWARK, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) today announced revised subscription rights in connection with its previously announced rights offering. Holders of record as of May 9, 2025 (the "Record Date") will be eligible to participate in the rights offering. To be considered a Holder of record on the Record Date, prospective Holders must complete open market purchases by May 8, 2025. Former holders of Cyclo Therapeutics, Inc. who did not hold shares in street name and have not submitted their letter of transmittal to Equiniti Trust Company LLC (the Company's transfer agent), and wish to participate in the rights offering, should send their

      5/5/25 7:00:00 AM ET
      $RFL
      Real Estate
      Finance
    • Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

      NEWARK, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) today announced a rights offering, including key dates and terms. The planned offering is designed to provide existing stockholders and holders of our public warrants ("Holders") the opportunity to purchase additional shares of Rafael Holdings' Class B common stock, par value $0.01 per share ("Class B Common Stock"), subject to the terms outlined below for an aggregate offering of $25 million. The funds provide the Company additional capital for the potential launch of Trappsol® Cyclo™ in the event of a positive interim result from the 48-week interim analysis of the TransportNPC™ Phase 3 clinical t

      4/29/25 4:30:00 PM ET
      $RFL
      Real Estate
      Finance
    • Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role

      Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) today announced that, following the merger with Cyclo Therapeutics, Bill Conkling will be stepping down as CEO and assuming an advisory role with the Company. Rafael's Executive Chairman and Chairman of the Board, Howard Jonas will assume the role of CEO. During his tenure as CEO, Bill played a pivotal role in identifying investment opportu

      4/24/25 4:15:00 PM ET
      $RFL
      Real Estate
      Finance

    $RFL
    Financials

    Live finance-specific insights

    See more
    • Rafael Holdings Provides Update on Rafael Pharmaceuticals' Two Phase 3 Trials of CPI-613® (Devimistat), AVENGER 500 in Metastatic Pancreatic Cancer and ARMADA 2000 in Relapsed or Refractory Acute Myeloid Leukemia

      Phase 3 Clinical Trial in Metastatic Pancreatic Cancer Did Not Meet its Primary Endpoint of Improved Overall Survival Independent Data Monitoring Committee Recommended the Phase 3 Clinical Trial in Relapsed or Refractory Acute Myeloid Leukemia Be Stopped Due to Lack of Efficacy Rafael Holdings to Host Conference Call Today at 8:00 a.m. ET NEWARK, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE:RFL), a holding company focused on developing novel cancer metabolism therapeutics through its Barer Institute, investment in Rafael Pharmaceuticals, Inc. ("Rafael Pharmaceuticals") as well as other investments in early-stage ventures, today announced that the AVENGER 500 Phas

      10/28/21 7:00:00 AM ET
      $RFL
      Real Estate
      Finance

    $RFL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Rafael Holdings Inc.

      SC 13D/A - Rafael Holdings, Inc. (0001713863) (Subject)

      9/30/24 5:40:03 PM ET
      $RFL
      Real Estate
      Finance
    • Amendment: SEC Form SC 13D/A filed by Rafael Holdings Inc.

      SC 13D/A - Rafael Holdings, Inc. (0001713863) (Subject)

      6/18/24 6:12:11 PM ET
      $RFL
      Real Estate
      Finance
    • SEC Form SC 13D/A filed by Rafael Holdings Inc. (Amendment)

      SC 13D/A - Rafael Holdings, Inc. (0001713863) (Filed by)

      10/24/23 4:43:18 PM ET
      $RFL
      Real Estate
      Finance

    $RFL
    Leadership Updates

    Live Leadership Updates

    See more
    • Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

      Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common

      8/22/24 6:50:00 AM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

      Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common stock to Cyclo Therapeutics' shareholders, based on an exchange ratio

      8/22/24 6:50:00 AM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.

      CRANBURY, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. ("Cornerstone" or the "Company"), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the appointment of Jason Locasale, Ph.D., as a member of the Company's Scientific Advisory Board. Dr. Locasale is a highly respected scholar and brings to Cornerstone deep expertise in cancer metabolism, metabolomics, nutrition and the metabolic interface of epigenetics. "Dr. Locasale is an internationally recognized leader in the use of metabolomics approaches to study cancer biology and metabolism," said Sanjeev Luther, President & CEO at Cornerstone Pharmaceutical

      7/6/22 8:00:00 AM ET
      $RFL
      Real Estate
      Finance

    $RFL
    SEC Filings

    See more
    • Rafael Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - Rafael Holdings, Inc. (0001713863) (Filer)

      5/6/25 4:49:29 PM ET
      $RFL
      Real Estate
      Finance
    • SEC Form 424B3 filed by Rafael Holdings Inc.

      424B3 - Rafael Holdings, Inc. (0001713863) (Filer)

      5/6/25 4:40:50 PM ET
      $RFL
      Real Estate
      Finance
    • Amendment: SEC Form 8-K/A filed by Rafael Holdings Inc.

      8-K/A - Rafael Holdings, Inc. (0001713863) (Filer)

      5/5/25 7:15:49 AM ET
      $RFL
      Real Estate
      Finance

    $RFL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Conkling William was granted 27,454 units of Class B Common Stock, increasing direct ownership by 5% to 564,455 units (SEC Form 4)

      4 - Rafael Holdings, Inc. (0001713863) (Issuer)

      4/24/25 3:18:53 PM ET
      $RFL
      Real Estate
      Finance
    • New insider Sieger Markus claimed ownership of 155,182 units of Class B Common Stock (SEC Form 3)

      3 - Rafael Holdings, Inc. (0001713863) (Issuer)

      4/2/25 10:56:32 AM ET
      $RFL
      Real Estate
      Finance
    • Chief Financial Officer Polinsky David covered exercise/tax liability with 2,378 units of Class B Common Stock, decreasing direct ownership by 1% to 193,540 units (SEC Form 4)

      4 - Rafael Holdings, Inc. (0001713863) (Issuer)

      3/25/25 4:40:08 PM ET
      $RFL
      Real Estate
      Finance